Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. The company has a research collaboration with BIND Therapeutics, Inc. to develop ACCURINS for treatment of a range of cells with novel therapeutic payloads. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) insidermonkey.com This one’s a bit counter intuitive. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced on Friday that it had reached an FDA mid cycle review milestone. When a company submits a new drug application, the FDA will generally set up a couple of review period milestones, designed to improve communication between the agency and the company seeking approval. As these milestones are reached, it’s sort of hurdle clearing, and means the drug under review is a step closer to commercialization. As a general rule, therefore, when the review clears one of these milestones, a company will pick up a bit of strength on the back of the announcement. Not so in this instance, however. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) kicked off Friday’s session at $3.83 a share. By session close, the company traded for $3.61 – a 5.74% decline throughout the day. After hours, the company’s market capitalization slipped further, and will now open the week at $3.55, or a market capitalization for $648 million. So why the decline? Well, we also saw a bit of data released concerning the company’s ongoing irritable bowel syndrome with constipation (IBS-C) program. The program has been plagued with enrollment issues, and as such, there is going to be a slight delay on topline release from two phase IIIs. The data is now expected during the fourth quarter of this year, with a view to submitting an NDA to the FDA in this indication at some point during the first quarter of next year.
Synergy Pharma (SGYP) Announces Positive Top-Line Results from First Phase 3 Trial of Plecanatide Source: http://www.streetinsider.com/Corpor...st+Phase+3+Trial+of+Plecanatide/12328304.html
Does anyone know the reason for the dip? The news article I linked above was what I found, and it sounded positive from the headline and first paragraph. To be up front, I'm not invested in it or planning on getting in any more bios right now, so I didn't read the full article.
Bull Bear thesis will be confirmed today. $6 target, Next target 6. 29. If not 5.40 in a heartbeat. Should be easy with bo rumors.
SGYP after a +21% in one day a little pull back by take profit is natural; no fear longs remain strong !
SGYP still going strong here. Really no give back since the breakout late last month. Up another +8% today to new 52-week highs.
Synergy Pharmaceuticals (SGYP +6.88%) climbed 3% in after-hours trading after it was rated a new 'Outperform' at Oppenheimer with a price target of $10.
We expect quite a number of M&A deals in health-care in 2017. In particular, pharma and bio space will see heightened levels activity pathway likely been further cleared with Trump as deals will accelerate after years of regulatory roadblocks under prior administration. We expect much of the activity in the small- and mid-sized names.
